fenofibrate has been researched along with 3-hydroxy-3-methylglutaryl-coenzyme a in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hahn, C; von Bergmann, K | 1 |
| Bordet, R; Destée, A; Gelé, P; Kreisler, A; Lhermitte, M; Wiart, JF | 1 |
| Ashok, P; Poulose, DN; Singh, D; Suresh, B | 1 |
3 other study(ies) available for fenofibrate and 3-hydroxy-3-methylglutaryl-coenzyme a
| Article | Year |
|---|---|
Relationship between the serum concentration of 7 alpha-hydroxycholesterol and fecal bile acid excretion in humans.
Topics: Acyl Coenzyme A; Adolescent; Adult; Aged; Bile Acids and Salts; Child; Child, Preschool; Feces; Female; Fenofibrate; Gas Chromatography-Mass Spectrometry; Humans; Hydroxycholesterols; Hypercholesterolemia; Hypolipidemic Agents; Male; Metabolic Diseases; Middle Aged | 1996 |
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acyl Coenzyme A; Analysis of Variance; Animals; Bezafibrate; Cell Death; Disease Models, Animal; Drug Interactions; Fenofibrate; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; MPTP Poisoning; PPAR alpha; Substantia Nigra | 2007 |
Evaluation of antihyperlipidemic potency of a polyherbomineral formulation (AF-LIP) in experimental animal models.
Topics: Acyl Coenzyme A; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Feces; Female; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Plant Extracts; Polyethylene Glycols; Rats; Rats, Wistar; Simvastatin | 2014 |